[
  {
    "date": "2023-12-30",
    "symbol": "ASLN",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "ASLAN Pharmaceuticals Limited",
    "entitycentralindexkey": 1722926,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": 587074700,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "security12btitle": "American Depositary Shares (ADSs), each representing twenty-five ordinary shares, par value $0.01 per share",
    "tradingsymbol": "ASLN",
    "securityexchangename": "NASDAQ",
    "notradingsymbolflag": "true",
    "entityfilenumber": "001-38475",
    "entityincorporationstatecountrycode": "E9",
    "cityareacode": 65,
    "localphonenumber": "6817 9598",
    "contactpersonnelname": "Carl Firth",
    "entityaddressaddressline1": "3 Temasek Avenue Level 18 Centennial Tower",
    "entityaddresscityortown": "Singapore",
    "entityaddresscountry": "SG",
    "entityaddresspostalzipcode": 39190,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelemailaddress": "investor@aslanpharma.com",
    "icfrauditorattestationflag": "true",
    "documentfinstmterrorcorrectionflag": "false",
    "auditorfirmid": 1046,
    "auditorname": "Deloitte & Touche LLP",
    "auditorlocation": "Singapore",
    "cashandcashequivalents": 21252058,
    "othercurrentassets": 2877934,
    "currentassets": 24129992,
    "fairvalueofinvestmentsinequityinstrumentsdesignatedasmeasuredatfairvaluethroughothercomprehensiveincome": 235567,
    "propertyplantandequipment": 29268,
    "rightofuseassets": 229982,
    "intangibleassetsotherthangoodwill": 1716,
    "noncurrentassets": 496533,
    "assets": 24626525,
    "tradeandothercurrentpayablestotradesuppliers": 7918607,
    "othercurrentpayables": 3081329,
    "shorttermborrowings": 1800387,
    "currentleaseliabilities": 226187,
    "currentfinancialliabilitiesatfairvaluethroughprofitorloss": 88394,
    "currentliabilities": 13114904,
    "longtermborrowings": 24798552,
    "noncurrentliabilities": 24798552,
    "liabilities": 37913456,
    "issuedcapital": 63931993,
    "capitalsurplus": 243791693,
    "retainedearnings": -321067236,
    "otherequityinterest": 56619,
    "equityattributabletoownersofparent": -13286931,
    "equity": -13286931,
    "equityandliabilities": 24626525,
    "revenuefromcontractswithcustomers": 12000000,
    "grossprofit": 12000000,
    "generalandadministrativeexpense": 13240218,
    "researchanddevelopmentexpense": 42495379,
    "operatingexpense": 55735597,
    "profitlossfromoperatingactivities": -43735597,
    "revenuefrominterest": 404981,
    "otherincome": 462321,
    "othergainslosses": 3121606,
    "financecosts": 4331661,
    "netnonoperatingincomeexpense": -342753,
    "shareofprofitlossofcontinuingoperationsofassociatesandjointventuresaccountedforusingequitymethod": -8587,
    "profitlossbeforetax": -44086937,
    "incometaxexpensecontinuingoperations": 132667,
    "profitloss": -44219604,
    "othercomprehensiveincomebeforetaxgainslossesfrominvestmentsinequityinstruments": 235567,
    "comprehensiveincome": -43984037,
    "profitlossattributabletoownersofparent": -44219604,
    "comprehensiveincomeattributabletoownersofparent": -43984037,
    "basicearningslosspershare": -0.11,
    "dilutedearningslosspershare": -0.11,
    "numberofsharesissued": 439926480,
    "issueofequity": 912031,
    "increasedecreaseinnumberofordinarysharesissued": 91203115,
    "issuanceofprefundedwarrantvalue": 8262698,
    "issuanceoftranchewarrantsvalue": 3712402,
    "expiryoftranchewarrantsvalue": -1539117,
    "shareissuerelatedcost": 93805,
    "increasedecreasethroughsharebasedpaymenttransactions": 2769279,
    "othercomprehensiveincome": 235567,
    "proceedsfromissueofordinaryshares": 23027787,
    "financialliabilitiesmeasuredatfairvaluethroughprofitorloss": 3465180,
    "reclassificationadjustmentsfromequityinstrumentstoaccumulateddeficit": 1539897,
    "adjustmentsfordepreciationexpense": 344378,
    "adjustmentsforamortisationexpense": 4120,
    "netgainlossesonchangesinfairvalueoffinancialassetsandliabilitiesroutedthroughprofitorloss": 3466999,
    "adjustmentsforfinancecosts": 4331661,
    "adjustmentsforinterestincome": 125825,
    "adjustmentsforinterestincomefrommoneymarketfund": 279156,
    "adjustmentsforsharebasedpaymentandlongtermincentiveplan": 2703200,
    "adjustmentsforgainlossondisposalspropertyplantandequipment": 148,
    "adjustmentsforunrealisedforeignexchangelossesgains": 198842,
    "adjustmentsfordecreaseincreaseinotherassets": 1097877,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -4865880,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": 816241,
    "cashflowsfromusedinoperations": -43320039,
    "interestreceivedclassifiedasoperatingactivities": 125825,
    "interestpaidclassifiedasoperatingactivities": 3318576,
    "incometaxespaidrefundclassifiedasoperatingactivities": 126208,
    "cashflowsfromusedinoperatingactivities": -46638998,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 10781,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 148,
    "proceedsfrominterestincomeonmoneymarketfund": 279156,
    "cashflowsfromusedininvestingactivities": 268523,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 12000000,
    "paymentsforproceedsfromleaseliabilitiesclassifiedasfinancingactivities": -296920,
    "repaymentofinterestportionofleaseliabilities": -10411,
    "proceedsfromissuingshares": 7681312,
    "issuanceofprefundedwarrantsandtranchewarrantsclassifiedasequityinstruments": 11975100,
    "issuanceoftranchewarrantsclassifiedasfinancialliabilities": 3465180,
    "paymentsfortransactioncostsattributabletoissuanceofordinaryshares": 93805,
    "cashflowsfromusedinfinancingactivities": 10720456,
    "increasedecreaseincashandcashequivalents": -35650019,
    "titleofnewifrs": "IFRS 10 and IAS 28 (amendments)",
    "descriptionofnatureofimpendingchangeinaccountingpolicy": "Sale or Contribution of Assets between an Investor and its Associate or Joint Venture",
    "cashonhand": 648,
    "balanceswithbanks": 21251410,
    "cash": 21252058,
    "otherreceivables": 171441,
    "currentprepayments": 1681465,
    "currentrefundabledeposits": 1025028,
    "financialliabilitiesatfairvaluethroughprofitorloss": 87693,
    "nameofinvestor": "ASLAN   Pharmaceuticals   Limited (\"ASLAN    Cayman\")",
    "nameofsubsidiary": "ASLAN   Pharmaceuticals   Pte. Ltd.",
    "natureofactivities": "New drug researchand development",
    "proportionofownershipinterestinsubsidiary": 1,
    "proportionofownershipinterestinassociate": 0.35,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": 8587,
    "tradeandotherpayablestotradesuppliers": 7918607,
    "currentrecognisedliabilitiesdefinedbenefitplan": 46699,
    "shorttermemployeebenefitsaccruals": 1748901,
    "payablesforprofessionalfeescurrent": 1098536,
    "otherliabilities": 187193,
    "othercurrentpayablesmaturityondemandorwithinoneyear": 3081329,
    "borrowings": 26598939,
    "principalloanamount": 7509524,
    "parvaluepershare": 0.01,
    "fairvalueofwarrants": 87693,
    "differenceoffairvalueofwarrants": 2520,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 40788,
    "numberofsharesauthorised": 1000000000,
    "numberofsharesissuedandfullypaid": 439926480,
    "sharepremium": 219774205,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 89462,
    "prefundedwarrantsfairvaluerevaluedamount": 701,
    "gainlossfairvaluevaluationofwarrants": 3464479,
    "dateofagreement": "2015-12-31",
    "dateofagreementamended": "2018-03-31",
    "firstpaymentuponcommencement": 30000000,
    "regulatorymilestoneslinkedpaymentsestimated": 95000000,
    "salesmilestoneslinkedpaymentsestimated": 655000000,
    "percentageoflicensingrevenue": 0.1,
    "upfrontpayment": 12000000,
    "adsissuancecontribution": 386908,
    "governmentgrantsforresearchanddevelopmentexpenditures": 73724,
    "miscellaneousotheroperatingincome": 1689,
    "nonoperatingincomeother": 386908,
    "netforeignexchangegainloss": -332725,
    "gainslossesondisposalsofpropertyplantandequipment": 148,
    "netgainlossesonchangesinfairvalueoffinanacialassetsandliabilitiesroutedthroughprofitorloss": 3466999,
    "othersincomeexpenses": -12816,
    "interestexpense": 442410,
    "interestonotherlongtermborrowing": 3871299,
    "interestexpenseonleaseliabilities": 13074,
    "otherfinancecost": 4878,
    "depreciationandamortisationexpense": 319725,
    "shorttermemployeebenefitsexpense": 9622503,
    "postemploymentbenefitexpensedefinedbenefitplans": 415509,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 2769279,
    "expenseincomefromcashsettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": -66079,
    "employeebenefitsexpense": 12741212,
    "employeebenefitsexpenserelatedtogeneralandadministrativefunction": 7148068,
    "employeebenefitsexpenserelatedtoresearchanddevelopment": 5593144,
    "currenttaxexpenseincome": 113251,
    "adjustmentsforcurrenttaxofpriorperiod": 19416,
    "accountingprofit": -44086937,
    "taxexpenseincomeatapplicabletaxrate": -7494779,
    "taxeffectofexpenserevenueexemptfromtaxation": 83729,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 549230,
    "taxcreditsrelatedtoexpenditureonresearchanddevelopment": 161510,
    "taxeffectoftaxlosses": 6396624,
    "taxeffectofshareofresultsofassociatesandjointventure": 1460,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 738497,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 275000000,
    "applicabletaxrate": 0.17,
    "corporatesurtaxrate": 0.05,
    "federalincometaxrate": 0.21,
    "stateincometaxrate": 0.087,
    "weightedaverageshares": 411242644,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 786827,
    "sharebasedcompensationarrangementbysharebasedpaymentawardgrantedexpirationperiod": "P10Y",
    "numberofinstrumentsotherequityinstrumentsgranted": 62030922,
    "percentageofincreaseinoutstandingshares": 0.04,
    "exercisepriceofoutstandingshareoptions2019": 6.8,
    "expensefromsharebasedpaymenttransactionswithemployees": 2769279,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest.",
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 56700,
    "numberofotherequityinstrumentsredeemedinsharebasedpaymentarrangement": 62910,
    "reportingdatefairvalueofaward": 0.52,
    "recognizednetcompensationexpensebenefit": -66079,
    "recognizedcompensationliabilitiescurrent": 46699,
    "sharebasedpaymentarrangementintrinsicvalue": 234448,
    "numberofoutstandingshareoptions": 322769,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 48800,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 333,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 322769,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 22.74,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 2.93,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement2019": 17.08,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 31.9,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 22.74,
    "weightedaveragefairvalueofeachoptiongrantedinsharebasedpaymentarrangement2019": 2.73,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P0Y6M",
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 89462,
    "liabilitiesarisingfromfinancingactivities": 226187,
    "interestpaidclassifiedasfinancingactivities": 10411,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": 307436,
    "increasedecreasethroughotherchangesliabilitiesarisingfromfinancingactivities": -2663,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfrominterestexpense": 13074,
    "noncurrentfinancialassetsatfairvaluethroughothercomprehensiveincome": 235567,
    "borrowingsadjustmenttointerestratebasis": 0.01,
    "increaseinpretaxlossduetohundredbasispointincreaseininterestrates": 265989,
    "issuesfairvaluemeasurementliabilities": 3465180,
    "gainslossesrecognisedinprofitorlossfairvaluemeasurementliabilities": -2520,
    "gainslossesrecognisedinothercomprehensiveincomefairvaluemeasuremententitysownequityinstruments": 235567,
    "descriptionofvaluationtechniquesandkeyinputs": "Option Pricing Model (Binomial Tree Model).The following variable were taken into consideration: Time to maturity, current share price, strike price, risk free rate, dividend yield and volatility",
    "descriptionsignificantunobservableinputs": "Volatility",
    "descriptionofsensitivityoffairvaluemeasurementtochangesinunobservableinputs": "The higher the volatility, the higher the fair value. If the volatility was 5 per cent lower while all other variables were held constant, the carrying amount would decrease by US$3,631. If the volatility was 5 per cent higher while all other variables were held constant, the carrying amount would increase by US$3,171.",
    "percentageofreasonablypossibleincreaseinunobservableinputliabilities": 0.05,
    "percentageofreasonablypossibledecreaseinunobservableinputliabilities": 0.05,
    "percentageofreasonablypossibleincreaseinunobservableinputentitysownequityinstruments": 0.05,
    "percentageofreasonablypossibledecreaseinunobservableinputentitysownequityinstruments": 0.05,
    "increasedecreaseinfairvaluemeasurementduetoreasonablypossibleincreaseinunobservableinputliabilities": 3171,
    "increasedecreaseinfairvaluemeasurementduetoreasonablypossibledecreaseinunobservableinputliabilities": 3631,
    "increasedecreaseinfairvaluemeasurementduetoreasonablypossibledecreaseinunobservableinputentitysownequityinstruments": 1314,
    "increasedecreaseinfairvaluemeasurementduetoreasonablypossibleincreaseinunobservableinputentitysownequityinstruments": 1367,
    "financialassetsatamortisedcost": 22448527,
    "financialliabilitiesatamortisedcost": 36910284,
    "financialassetsexposedtoforeigncurrencyrisk": 2825324,
    "financialassetsexchangerate": 0.7577,
    "financialassetscarryingvalue": 2140748,
    "financialliabilitiesexposedtoforeigncurrencyrisk": 18232233,
    "financialliabilitiesexchangerate": 0.7577,
    "financialliabilitiescarryingvalue": 13814563,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -583691,
    "tradepayablesundiscountedcashflows": 7918607,
    "otherpayableundiscountedcashflows": 3081329,
    "grossleaseliabilities": 226187,
    "derivativefinancialliabilitiesundiscountedcashflows": 87693,
    "nameofultimateparentofgroup": "Other",
    "descriptionofnatureofrelatedpartyrelationship": "Key Management Personnel",
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 3115619,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 140332,
    "keymanagementpersonnelcompensationcashsettledsharebasedcompensation": 2256528,
    "keymanagementpersonnelcompensation": 5512479,
    "directorsremunerationexpense": 280417,
    "numberofreportablesegment": 1
  },
  {
    "date": "2022-12-31",
    "symbol": "ASLN",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "ASLAN Pharmaceuticals Limited",
    "entitycentralindexkey": 1722926,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": "null",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "security12btitle": "Ordinary shares, par value $0.01 per share *",
    "tradingsymbol": "ASLN",
    "securityexchangename": "Nasdaq",
    "notradingsymbolflag": "true",
    "entityfilenumber": "001-38475",
    "entityincorporationstatecountrycode": "Cayman Islands",
    "cityareacode": 65,
    "localphonenumber": "6817 9598",
    "contactpersonnelname": "Carl Firth",
    "entityaddressaddressline1": "3 Temasek Avenue Level 18 Centennial Tower",
    "entityaddresscityortown": "Singapore ",
    "entityaddresscountry": "Singapore",
    "entityaddresspostalzipcode": 39190,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelemailaddress": " investor@aslanpharma.com",
    "icfrauditorattestationflag": "false",
    "auditorfirmid": 1046,
    "auditorname": "Deloitte & Touche LLP ",
    "auditorlocation": "Singapore",
    "cashandcashequivalents": "null",
    "othercurrentassets": "null",
    "currentassets": 54906,
    "investmentsinassociates": 8587,
    "propertyplantandequipment": 43140,
    "rightofuseassets": 249601,
    "intangibleassetsotherthangoodwill": 5836,
    "noncurrentassets": 307164,
    "assets": "null",
    "tradeandothercurrentpayablestotradesuppliers": "null",
    "othercurrentpayables": "null",
    "shorttermborrowings": "null",
    "currentleaseliabilities": 215671,
    "currentfinancialliabilitiesatfairvaluethroughprofitorloss": 90213,
    "currentliabilities": 30371,
    "longtermborrowings": "null",
    "noncurrentliabilities": "null",
    "liabilities": "null",
    "issuedcapital": "null",
    "capitalsurplus": "null",
    "retainedearnings": 279000000,
    "otherequityinterest": -178948,
    "equityattributabletoownersofparent": "null",
    "equity": 24535,
    "equityandliabilities": "null",
    "generalandadministrativeexpense": "null",
    "researchanddevelopmentexpense": "null",
    "operatingexpense": "null",
    "profitlossfromoperatingactivities": "-null",
    "revenuefrominterest": 354457,
    "otherincome": 386138,
    "othergainslosses": -29583,
    "financecosts": "null",
    "netnonoperatingincomeexpense": "-null",
    "shareofprofitlossofcontinuingoperationsofassociatesandjointventuresaccountedforusingequitymethod": -436032,
    "profitlossbeforetax": 377994,
    "incometaxexpensecontinuingoperations": 99221,
    "profitloss": "-null",
    "comprehensiveincome": "null",
    "profitlossattributabletoownersofparent": "-null",
    "comprehensiveincomeattributabletoownersofparent": "-null",
    "basicanddilutedearningslosspershare": -0.74,
    "numberofsharesissued": "null",
    "increasedecreasethroughsharebasedpaymenttransactions": "null",
    "adjustmentsfordepreciationexpense": 327632,
    "adjustmentsforamortisationexpense": 4120,
    "netgainlossesonchangesinfairvalueoffinancialassetsandliabilitiesroutedthroughprofitorloss": 133139,
    "adjustmentsforfinancecosts": "null",
    "adjustmentsforinterestincome": 1312,
    "adjustmentsforinterestincomefrommoneymarketfund": 353145,
    "adjustmentsforsharebasedpaymentandlongtermincentiveplan": "null",
    "adjustmentsforgainlossondisposalspropertyplantandequipment": 1172,
    "adjustmentsforunrealisedforeignexchangelossesgains": 88866,
    "gainlossonleasetermination": 14115,
    "adjustmentsforinterestaccretionincomeonshortterminvestmentnetofmanagementfee": -87493,
    "otheradjustmentstoreconcileprofitloss": 50109,
    "adjustmentsfordecreaseincreaseinotherassets": -357724,
    "adjustmentsforincreasedecreaseintradeaccountpayable": "null",
    "adjustmentsforincreasedecreaseinotheroperatingpayables": 41545,
    "cashflowsfromusedinoperations": "-null",
    "interestreceivedclassifiedasoperatingactivities": 1312,
    "interestpaidclassifiedasoperatingactivities": "null",
    "incometaxespaidrefundclassifiedasoperatingactivities": 105000,
    "cashflowsfromusedinoperatingactivities": "null",
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 27111,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 1172,
    "proceedsfrominterestincomeonmoneymarketfund": 353145,
    "purchaseofshortterminvestments": "null",
    "proceedsfromshortterminvestments": "null",
    "cashflowsfromusedininvestingactivities": 414699,
    "proceedsfromborrowingsclassifiedasfinancingactivities": "null",
    "paymentsforproceedsfromleaseliabilitiesclassifiedasfinancingactivities": -262798,
    "repaymentofinterestportionofleaseliabilities": -12544,
    "cashflowsfromusedinfinancingactivities": "null",
    "increasedecreaseincashandcashequivalents": "-null",
    "ratioofordinarysharesonnoncashequitytransaction": 5,
    "changeinratioofordinarysharesonnoncashequitytransaction": 25,
    "titleofnewifrs": "Amendments to IFRS 16",
    "descriptionofnatureofimpendingchangeinaccountingpolicy": "Lease Liability in a Sale and Leaseback",
    "cashonhand": 256,
    "balanceswithbanks": "null",
    "moneymarketfund": "null",
    "cash": "null",
    "currentprepayments": "null",
    "currentrefundabledeposits": "null",
    "financialassetsatfairvaluethroughprofitorloss": "null",
    "financialliabilitiesatfairvaluethroughprofitorloss": 90213,
    "nameofinvestor": "ASLAN   Pharmaceuticals   Pte. Ltd.",
    "nameofassociate": "Jaguahr Therapeutics   Pte. Ltd.   (“JAGUAHR”)",
    "nameofsubsidiary": "ASLAN   Pharmaceuticals   Taiwan Limited",
    "natureofactivities": "New drug researchand development",
    "proportionofownershipinterestinsubsidiary": 1,
    "proportionofownershipinterestinassociate": 0.35000000000000003,
    "investmentsinassociatesaccountedforusingequitymethod": 24535,
    "unrecognisedshareofprofitlossesofassociates": -436032,
    "otherlossonassociatesaccountedusingequitymethod": -50109,
    "intangibleassetsotherthangoodwillcarryingamountofrevaluedassets": 5836,
    "tradeandotherpayablestotradesuppliers": "null",
    "currentrecognisedliabilitiesdefinedbenefitplan": 234448,
    "shorttermemployeebenefitsaccruals": "null",
    "payablesforprofessionalfeescurrent": 560578,
    "otherliabilities": 154385,
    "othercurrentpayablesmaturityondemandorwithinoneyear": "null",
    "borrowings": "null",
    "principalloanamount": "null",
    "subsequenttotermloansmonthlyinterestonlypaymentsperiod": "July 1, 2021, to July 31, 2023",
    "parvaluepershare": 0.01,
    "fairvalueofwarrants": 90213,
    "differenceoffairvalueofwarrants": 133139,
    "numberofsharesauthorised": "null",
    "numberofsharesissuedandfullypaid": "null",
    "authorizedcapital": "null",
    "sharepremium": "null",
    "dateofagreement": "December 31, 2015",
    "dateofagreementamended": "March 31, 2018",
    "firstpaymentuponcommencement": 30000000,
    "regulatorymilestoneslinkedpaymentsestimated": 95000000,
    "salesmilestoneslinkedpaymentsestimated": 655000000,
    "percentageoflicensingrevenue": 0.1,
    "milestonepayment": 1000000,
    "governmentgrantsforresearchanddevelopmentexpenditures": 248613,
    "revenuefromgovernmentgrants": 29147,
    "interestrevenueexpense": 94248,
    "miscellaneousotheroperatingincome": 14130,
    "netforeignexchangegainloss": -85869,
    "gainslossesondisposalsofpropertyplantandequipment": 1172,
    "netgainlossesonchangesinfairvalueoffinanacialassetsandliabilitiesroutedthroughprofitorloss": 133139,
    "othersincomeexpenses": -78025,
    "interestexpense": 431052,
    "interestonotherlongtermborrowing": "null",
    "interestexpenseonleaseliabilities": 12544,
    "otherfinancecost": 7724,
    "depreciationandamortisationexpense": 331752,
    "shorttermemployeebenefitsexpense": "null",
    "postemploymentbenefitexpensedefinedbenefitplans": 355434,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": "null",
    "expenseincomefromcashsettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": -467134,
    "employeebenefitsexpense": "null",
    "employeebenefitsexpenserelatedtogeneralandadministrativefunction": "null",
    "employeebenefitsexpenserelatedtoresearchanddevelopment": "null",
    "currenttaxexpenseincome": 79379,
    "adjustmentsforcurrenttaxofpriorperiod": 19842,
    "accountingprofit": "-null",
    "taxexpenseincomeatapplicabletaxrate": "-null",
    "taxeffectofrevenuesexemptfromtaxation2011": 19769,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 361600,
    "taxcreditsrelatedtoexpenditureonresearchanddevelopment": 245802,
    "taxeffectoftaxlosses": "null",
    "taxeffectofshareofresultsofassociatesandjointventure": 74125,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 917106,
    "otherstaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": -17811,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 238000000,
    "applicabletaxrate": 0.2,
    "corporatesurtaxrate": 0.05,
    "federalincometaxrate": 0.21,
    "stateincometaxrate": 0.087,
    "numberofunitsinamericandepositaryshares": 5,
    "weightedaverageshares": "null",
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardgrantedexpirationperiod": 10,
    "numberofinstrumentsotherequityinstrumentsgranted": "null",
    "percentageofincreaseinoutstandingshares": 0.04,
    "exercisepriceofoutstandingshareoptions2019": 0.5,
    "expensefromsharebasedpaymenttransactionswithemployees": 132200,
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "The 241,142 bonus entitlement units granted under the 2018 LTIP will be one-third vested each year after the first, second, and third anniversary of the award.",
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 283501,
    "reportingdatefairvalueofaward": 0.36,
    "recognizednetcompensationexpensebenefit": -467134,
    "recognizedcompensationliabilitiescurrent": 234448,
    "numberofoutstandingshareoptions": "null",
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 744372,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": "null",
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 0.52,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 0.51,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 0.52,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 0.52,
    "weightedaveragefairvalueofeachoptiongrantedinsharebasedpaymentarrangement2019": 0.52,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": 9.51,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 386950,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 386950,
    "liabilitiesarisingfromfinancingactivities": "null",
    "interestpaidclassifiedasfinancingactivities": "null",
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": "-null",
    "increasedecreasethroughotherchangesliabilitiesarisingfromfinancingactivities": 88866,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfrominterestexpense": "null",
    "originalinvestmentcost": "null",
    "fairvaluegainsfrominterestincome": 353145,
    "historicalvolatilityforsharessignificantunobservablesinputassets": 1.3290000000000002,
    "sensitivityanalysisrate": 0.05,
    "percentageofincreaseonexchangerateofforeigncurrency": 0.05,
    "percentageofdecreaseonexchangerateofforeigncurrency": 0.05,
    "borrowingsadjustmenttointerestratebasis": 0.009999999999999998,
    "increaseinpretaxlossduetohundredbasispointincreaseininterestrates": 69596,
    "financialassetsatamortisedcost": "null",
    "financialliabilitiesatamortisedcost": "null",
    "financialassetsexposedtoforeigncurrencyrisk": "null",
    "financialassetsexchangerate": 0.7461,
    "financialassetscarryingvalue": "null",
    "financialliabilitiesexposedtoforeigncurrencyrisk": "null",
    "financialliabilitiesexchangerate": 0.7461,
    "financialliabilitiescarryingvalue": "null",
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -521750,
    "nameofultimateparentofgroup": "Other",
    "descriptionofnatureofrelatedpartyrelationship": "Key Management Personnel",
    "keymanagementpersonnelcompensationshorttermemployeebenefits": "null",
    "keymanagementpersonnelcompensationpostemploymentbenefits": 332037,
    "keymanagementpersonnelcompensationcashsettledsharebasedcompensation": "null",
    "keymanagementpersonnelcompensation": "null",
    "directorsremunerationexpense": 242782,
    "numberofreportablesegment": 1,
    "lossonstockconversion": 3.68
  },
  {
    "date": "2021-12-31",
    "symbol": "ASLN",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "ASLAN Pharmaceuticals Ltd",
    "entitycentralindexkey": 1722926,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": "null",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "security12btitle": "Ordinary shares, par value $0.01 per share",
    "tradingsymbol": "ASLN",
    "securityexchangename": "The Nasdaq Global Market",
    "notradingsymbolflag": "true",
    "entityfilenumber": "001-38475",
    "entityincorporationstatecountrycode": "Cayman Islands",
    "contactpersonnelname": "Carl Firth",
    "entityaddressaddressline1": "83 Clemenceau Avenue #12-03 UE Square",
    "entityaddresscityortown": "Singapore",
    "entityaddresscountry": "Singapore",
    "entityaddresspostalzipcode": 239920,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelemailaddress": "investor@aslanpharma.com",
    "icfrauditorattestationflag": "false",
    "auditorfirmid": 1046,
    "auditorname": "Deloitte & Touche",
    "auditorlocation": "Taipei, Taiwan",
    "cashandcashequivalents": "null",
    "othercurrentassets": "null",
    "currentassets": "null",
    "investmentsinassociates": 494728,
    "propertyplantandequipment": 34979,
    "rightofuseassets": 197746,
    "intangibleassetsotherthangoodwill": 9956,
    "noncurrentassets": 737409,
    "assets": "null",
    "tradeandothercurrentpayablestotradesuppliers": "null",
    "othercurrentpayables": "null",
    "currentleaseliabilities": 199124,
    "currentfinancialliabilitiesatfairvaluethroughprofitorloss": 223352,
    "currentliabilities": 113674,
    "longtermborrowings": "null",
    "noncurrentliabilities": "null",
    "liabilities": "null",
    "issuedcapital": "null",
    "capitalsurplus": "null",
    "retainedearnings": "-null",
    "otherequityinterest": -178948,
    "equityattributabletoownersofparent": "null",
    "equity": "null",
    "equityandliabilities": "null",
    "generalandadministrativeexpense": "null",
    "researchanddevelopmentexpense": "null",
    "operatingexpense": "null",
    "profitlossfromoperatingactivities": "-null",
    "revenuefrominterest": 219,
    "otherincome": "null",
    "gainslossesrecognisedwhencontrolinsubsidiaryislost": "null",
    "othergainslosses": "null",
    "financecosts": "null",
    "netnonoperatingincomeexpense": "null",
    "shareofprofitlossofcontinuingoperationsofassociatesandjointventuresaccountedforusingequitymethod": -405712,
    "profitlossbeforetax": "-null",
    "profitloss": -268964,
    "comprehensiveincome": "-null",
    "profitlossattributabletoownersofparent": "-null",
    "profitlossattributabletononcontrollinginterests": -268964,
    "comprehensiveincomeattributabletoownersofparent": "-null",
    "comprehensiveincomeattributabletononcontrollinginterests": -268964,
    "basicanddilutedearningslosspershare": -0.1,
    "numberofsharesissued": "null",
    "issueofequity": "null",
    "increasedecreaseinnumberofordinarysharesissued": "null",
    "shareissuerelatedcost": "null",
    "increasedecreasethroughexerciseofoptions": 221710,
    "increasedecreasethroughexerciseofstockoptions": 590000,
    "increasedecreasethroughsharebasedpaymenttransactions": "null",
    "increasedecreasethroughexerciseofwarrantsequity": 825800,
    "numberofwarrantspurchaseexercised": "null",
    "noncontrollinginterestsderecognisedduetogainondilutionofsubsidiary": -31717,
    "increasedecreasethroughchangeinequityofsubsidiaries": "-null",
    "adjustmentsfordepreciationexpense": 279660,
    "adjustmentsforamortisationexpense": 2564,
    "netgainlossesonchangesinfairvalueoffinancialassetsandliabilitiesroutedthroughprofitorloss": -488255,
    "adjustmentsforfinancecosts": "null",
    "adjustmentsforinterestincome": 219,
    "adjustmentsforsharebasedpayments": "null",
    "adjustmentsforunrealisedforeignexchangelossesgains": -230619,
    "adjustmentsfordecreaseincreaseinotherassets": "-null",
    "adjustmentsforincreasedecreaseintradeaccountpayable": 797228,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": "-null",
    "adjustmentsforincreasedecreaseinothercurrentliabilities": -269735,
    "cashflowsfromusedinoperations": "-null",
    "interestreceivedclassifiedasoperatingactivities": 219,
    "cashflowsfromusedinoperatingactivities": "-null",
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 36448,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 12360,
    "increasedecreaseinrefundabledeposits": 20653,
    "cashflowsfromusedininvestingactivities": -28155,
    "proceedsfromborrowingsclassifiedasfinancingactivities": "null",
    "repaymentsofborrowingsclassifiedasfinancingactivities": "null",
    "paymentsforproceedsfromleaseliabilitiesclassifiedasfinancingactivities": -353649,
    "repaymentofinterestportionofleaseliabilities": -21510,
    "proceedsfromexerciseofoptions": "null",
    "proceedsfromissuingshares": "null",
    "paymentsfortransactioncostsattributabletoissuanceofordinaryshares": "null",
    "cashflowsfromusedinfinancingactivities": "-null",
    "increasedecreaseincashandcashequivalents": 576453,
    "titleofnewifrs": "Amendments to IAS 12",
    "descriptionofnatureofimpendingchangeinaccountingpolicy": "Deferred Tax related to Assets and Liabilities arising from a Single Transaction",
    "operatingleasesleaseterm": 3,
    "cashonhand": 294,
    "balanceswithbanks": "null",
    "cash": "null",
    "currentprepayments": "null",
    "currentrefundabledeposits": 879093,
    "financialliabilitiesatfairvaluethroughprofitorloss": 223352,
    "nameofinvestor": "ASLAN   Pharmaceuticals   Pte. Ltd.",
    "nameofsubsidiary": "Jaguahr Therapeutics   Pte.Ltd.   (“JAGUAHR”)",
    "natureofactivities": "Investment holding",
    "proportionofownershipinterestinsubsidiary": 0.35000000000000003,
    "reclassificationofcapitalreserve": "null",
    "noncontrollinginterestsderecognizedduetogainondilutionofsubsidiary": 31717,
    "percenatgeofthefairvalueofnetidentifiableassets": 0.35000000000000003,
    "principalplaceofbusinessofsubsidiary": "Singapore",
    "proportionofvotingrightsheldbynoncontrollinginterests": 0.65,
    "proportionofownershipinterestinassociate": 0.35000000000000003,
    "investmentsinassociatesaccountedforusingequitymethod": "null",
    "unrecognisedshareoflossesofassociates": 444619,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -50108,
    "intangibleassetsotherthangoodwillcarryingamountofrevaluedassets": 9956,
    "currentrecognisedliabilitiesdefinedbenefitplan": 701582,
    "shorttermemployeebenefitsaccruals": "null",
    "interestpayable": 142083,
    "payablesforprofessionalfeescurrent": 507340,
    "otherliabilities": 79488,
    "longtermborrowingsfromrelatedparties": "null",
    "borrowingsinterestratebasis": "6% plus LIBOR",
    "subsequenttotermloansmonthlyinterestonlypaymentsperiod": "July 1, 2021 to July 31, 2023",
    "parvaluepershare": 0.01,
    "fairvalueofwarrants": 223352,
    "differenceoffairvalueofwarrants": 464972,
    "numberofsharesauthorised": "null",
    "numberofsharesissuedandfullypaid": "null",
    "authorizedcapital": "null",
    "sharepremium": "null",
    "proceedsfromissueofordinaryshares": 14100000,
    "proceedsavailableforsaleunderagreement": 62800000,
    "dateofagreement": "2015-12-31",
    "dateofagreementamended": "2018-03-31",
    "firstpaymentuponcommencement": 30000000,
    "regulatorymilestoneslinkedpaymentsestimated": 95000000,
    "salesmilestoneslinkedpaymentsestimated": 655000000,
    "percentageoflicensingrevenue": 0.1,
    "adsissuancecontribution": "null",
    "revenuefromgovernmentgrants": 31112,
    "miscellaneousotheroperatingincome": 771,
    "nonoperatingincomeother": "null",
    "netforeignexchangegainloss": 512450,
    "netgainlossesonchangesinfairvalueoffinanacialassetsandliabilitiesroutedthroughprofitorloss": 594046,
    "miscellaneousothergainslosses": 14,
    "interestexpense": 443216,
    "interestonotherlongtermborrowing": "null",
    "interestonloansfromshareholders": 154773,
    "interestexpensefromrelatedparties": 4552,
    "interestexpenseonleaseliabilities": 21510,
    "depreciationandamortisationexpense": 282224,
    "shorttermemployeebenefitsexpense": "null",
    "postemploymentbenefitexpensedefinedbenefitplans": 257128,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": "null",
    "expenseincomefromcashsettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": -234761,
    "employeebenefitsexpense": "null",
    "employeebenefitsexpenserelatedtogeneralandadministrativefunction": "null",
    "employeebenefitsexpenserelatedtoresearchanddevelopment": "null",
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 207000000,
    "applicabletaxrate": 0.25,
    "decreaseinunappropriatedearningsduetoeffectofcorporatesurtaxrate": 0.05,
    "federalincometaxrate": 0.21,
    "stateincometaxrate": 0.087,
    "accountingprofit": "-null",
    "taxexpenseincomeatapplicabletaxrate": "-null",
    "taxeffectofrevenuesexemptfromtaxation2011": 464439,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 648651,
    "taxcreditsrelatedtoexpenditureonresearchanddevelopment": "null",
    "taxeffectoftaxlosses": "null",
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 609075,
    "numberofunitsinamericandepositaryshares": 5,
    "weightedaverageshares": "null",
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 282000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardgrantedexpirationperiod": 10,
    "numberofinstrumentsotherequityinstrumentsgranted": "null",
    "percentageofincreaseinoutstandingshares": 0.04,
    "expensefromsharebasedpaymenttransactionswithemployees": "null",
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "The 241,142 bonus entitlement units granted under the 2018 LTIP will be one-third vested each year after the first, second, and third anniversary of the award. The 491,020 bonus entitlement units granted under the 2019 LTIP will be one-third vested each year after the first, second, and third anniversary of the award.",
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 283501,
    "reportingdatefairvalueofaward": 1.12,
    "recognizednetcompensationbenefit": 234761,
    "recognizedcompensationliabilitiescurrent": 701582,
    "numberofoutstandingshareoptions": "null",
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 81000,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 3500,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": "null",
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 2.06,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 3.24,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 2.06,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 2.06,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 2.06,
    "weightedaveragefairvalueofeachoptiongrantedinsharebasedpaymentarrangement2019": 2.63,
    "exercisepriceofoutstandingshareoptions2019": 2.06,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P9Y4M9D",
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 386950,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 9928,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 257967,
    "liabilitiesarisingfromfinancingactivities": 142083,
    "interestpaidclassifiedasfinancingactivities": 117986,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": -688324,
    "increasedecreasethroughotherchangesliabilitiesarisingfromfinancingactivities": -124827,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfrominterestexpense": "null",
    "historicalvolatilityforsharessignificantunobservablesinputassets": 1.6030000000000002,
    "percentageofincreaseonexchangerateofforeigncurrency": 0.05,
    "sensitivityanalysisrate": 0.05,
    "percentageofdecreaseonexchangerateofforeigncurrency": 0.05,
    "borrowingsadjustmenttointerestratebasis": 0.009999999999999998,
    "increaseinpretaxlossduetohundredbasispointincreaseininterestrates": 308573,
    "financialassetsatamortisedcost": "null",
    "financialliabilitiesatamortisedcost": "null",
    "financialassetsexposedtoforeigncurrencyrisk": 837336,
    "financialassetsexchangerate": 0.7411,
    "financialassetscarryingvalue": 620563,
    "financialliabilitiesexposedtoforeigncurrencyrisk": "null",
    "financialliabilitiesexchangerate": 0.7411,
    "financialliabilitiescarryingvalue": "null",
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -548878,
    "nameofultimateparentofgroup": "Key Management Personnel",
    "descriptionofnatureofrelatedpartyrelationship": "Key Management Personnel/Other",
    "keymanagementpersonnelcompensationshorttermemployeebenefits": "null",
    "keymanagementpersonnelcompensationpostemploymentbenefits": 112095,
    "keymanagementpersonnelcompensationcashsettledsharebasedcompensation": "null",
    "keymanagementpersonnelcompensation": "null",
    "numberofreportablesegment": 1
  },
  {
    "date": "2020-12-31",
    "symbol": "ASLN",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "ASLAN Pharmaceuticals Ltd",
    "entitycentralindexkey": 1722926,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": 237663300,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "security12btitle": "Ordinary shares, par value $0.01 per share",
    "tradingsymbol": "ASLN",
    "securityexchangename": "NASDAQ",
    "notradingsymbolflag": "true",
    "entityfilenumber": "001-38475",
    "entityincorporationstatecountrycode": "E9",
    "contactpersonnelname": "Carl Firth",
    "entityaddressaddressline1": "83 Clemenceau Avenue #12-03 UE Square",
    "entityaddresscountry": "SG",
    "entityaddresspostalzipcode": 239920,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "contactpersonnelemailaddress": "investor@aslanpharma.com",
    "icfrauditorattestationflag": "false",
    "cashandcashequivalents": 14324371,
    "othercurrentreceivables": 528841,
    "prepayments": 511208,
    "currentfinancialassetsatfairvaluethroughprofitorloss": 137926,
    "currentassets": 807560,
    "financialassetsatfairvaluethroughprofitorloss": 137926,
    "propertyplantandequipment": 495183,
    "rightofuseassets": 462550,
    "intangibleassetsotherthangoodwill": 23116310,
    "refundabledeposits": 103307,
    "noncurrentassets": 579404,
    "assets": 16081750,
    "tradeandothercurrentpayablestotradesuppliers": 2319558,
    "othercurrentpayables": 4280409,
    "shorttermborrowings": 329270,
    "currentborrowingsfromrelatedparties": 67912,
    "currentleaseliabilities": 271624,
    "currentfinancialliabilitiesatfairvaluethroughprofitorloss": 267000,
    "currentliabilities": 139378,
    "longtermborrowings": 11123065,
    "noncurrentleaseliabilities": 281149,
    "othernoncurrentliabilities": 111990,
    "noncurrentliabilities": 15576560,
    "liabilities": 26234034,
    "issuedcapital": 61826237,
    "capitalsurplus": 123582460,
    "retainedearnings": -195682714,
    "otherequityinterest": -178948,
    "equityattributabletoownersofparent": 367501,
    "noncontrollinginterests": 300681,
    "equity": 668182,
    "equityandliabilities": 16081750,
    "generalandadministrativeexpense": 7169177,
    "researchanddevelopmentexpense": 9314120,
    "operatingexpense": 16483297,
    "profitlossfromoperatingactivities": -1718666,
    "revenuefrominterest": 592,
    "otherincome": 888046,
    "othergainslosses": -129299,
    "financecosts": 1247331,
    "netnonoperatingincomeexpense": -487992,
    "profitlossbeforetax": 3869726,
    "profitloss": -773400,
    "othercomprehensiveincomebeforetaxgainslossesfrominvestmentsinequityinstruments": -123864,
    "comprehensiveincome": -1718666,
    "profitlossattributabletoownersofparent": -945266,
    "profitlossattributabletononcontrollinginterests": -773400,
    "comprehensiveincomeattributabletoownersofparent": -945266,
    "comprehensiveincomeattributabletononcontrollinginterests": -773400,
    "basicanddilutedearningslosspershare": -0.08,
    "numberofsharesissued": 3953985,
    "issueofequity": 7643240,
    "increasedecreaseinnumberofordinarysharesissued": 19720500,
    "shareissuerelatedcost": 229297,
    "increasedecreasethroughsharebasedpaymenttransactions": 132200,
    "othercomprehensiveincome": -123864,
    "adjustmentsfordepreciationexpense": 295072,
    "adjustmentsforamortisationexpense": 2685,
    "netgainlossesonchangesinfairvalueoffinancialassetsandliabilitiesroutedthroughprofitorloss": -78038,
    "adjustmentsforfinancecosts": 1247331,
    "adjustmentsforinterestincome": 592,
    "adjustmentsforsharebasedpayments": 345836,
    "adjustmentsforgainlossondisposalspropertyplantandequipment": 968,
    "adjustmentsforunrealisedforeignexchangelossesgains": 206457,
    "adjustmentsfordecreaseincreaseinotheroperatingreceivables": -528841,
    "adjustmentsforincreasedecreaseinprepayments": -442285,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 447715,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": 425825,
    "cashflowsfromusedinoperations": -15051092,
    "interestreceivedclassifiedasoperatingactivities": 592,
    "interestpaidclassifiedasoperatingactivities": 2490,
    "cashflowsfromusedinoperatingactivities": -1655443,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 5056,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 1214,
    "increasedecreaseinrefundabledeposits": 4769,
    "cashflowsfromusedininvestingactivities": 927,
    "paymentsforproceedsfromleaseliabilitiesclassifiedasfinancingactivities": -202605,
    "repaymentofinterestportionofleaseliabilities": -37935,
    "proceedsfromissuingshares": 7643240,
    "paymentsfortransactioncostsattributabletoissuanceofordinaryshares": 229297,
    "cashflowsfromusedinfinancingactivities": -202605,
    "increasedecreaseincashandcashequivalents": -1655443,
    "nameofreportingentityorothermeansofidentification": "Jaguahr Therapeutics Pte. Ltd.",
    "countryofincorporation": "Singapore",
    "dateofincorporation": "2019-08",
    "mainbusinessofgroup": "New drug research and development",
    "titleofnewifrs": "Annual Improvements to IFRSStandards 2018-2020 Cycle",
    "descriptionofnatureofimpendingchangeinaccountingpolicy": "Amendments to IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 9 Financial Instruments, IFRS 16 Leases, and IAS 41 Agriculture",
    "cashonhand": 1709,
    "balanceswithbanks": 14322662,
    "cash": 14324371,
    "financialliabilitiesatfairvaluethroughprofitorloss": 267000,
    "nameofinvestor": "ASLAN Pharmaceuticals Pte. Ltd.",
    "nameofsubsidiary": "Jaguahr Therapeutics Pte. Ltd.",
    "natureofactivities": "New drug research and development",
    "proportionofownershipinterestinsubsidiary": 0.55,
    "principalplaceofbusinessofsubsidiary": "Singapore",
    "proportionofvotingrightsheldbynoncontrollinginterests": 0.45,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 5056,
    "depreciationpropertyplantandequipment": 29757,
    "disposalspropertyplantandequipment": 11220,
    "descriptionofusefullifepropertyplantandequipment": "3 years",
    "depreciationrightofuseassets": -265316,
    "grossleaseliabilities": 285243,
    "undiscountedoperatingleasepaymentstobereceived": 25868,
    "leaseliabilities": 552773,
    "discountratesoncapitalizedleasesinnominalterms": 0.06,
    "operatingleasesleaseterm": "P3Y",
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 107940,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 2732,
    "cashoutflowforleases": 426288,
    "leasecommitments": 2298,
    "amortisationintangibleassetsotherthangoodwill": 2685,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P3Y",
    "currentrecognisedliabilitiesdefinedbenefitplan": 1073593,
    "shorttermemployeebenefitsaccruals": 1492325,
    "interestpayable": 735510,
    "payablesforprofessionalfeescurrent": 837803,
    "otherliabilities": 141178,
    "longtermborrowingsincludinginterest": 2549152,
    "borrowingsredemptionandconversionpolicies": "(a) such outstanding principal amount and accrued and unpaid interest by (b) 90% of the volume-weighted average price of the Company’s ADSs on the date of the conversion notice. Each ADS represents five of the Company’s ordinary shares",
    "numberofunitsinamericandepositaryshares": 5,
    "postemploymentbenefitexpensedefinedbenefitplans": 200045,
    "numberofsharesauthorised": 500000000,
    "authorizedcapital": 165000000,
    "parvaluepershare": 0.01,
    "numberofsharesissuedandfullypaid": 209675470,
    "proceedsfromissueofordinaryshares": 7413943,
    "regulatorymilestoneslinkedpaymentsestimated": 95000000,
    "dateofagreement": "2016-10-31",
    "dateofagreementamended": "2018-03-31",
    "firstpaymentuponcommencement": 30000000,
    "salesmilestoneslinkedpaymentsestimated": 655000000,
    "percentageoflicensingrevenue": 0.1,
    "numberoftargetstoselect": 3,
    "numberofsharesreceivedinexchangeforsurrenderofresidualrights": 599445,
    "valueofsharesreceivedinexchangeforsurrenderofresidualrights": 255000,
    "numberofwarrantsreceivedinexchangeforsurrenderofresidualrights": 599445,
    "subscriptionprice": 0.32,
    "adsissuancecontribution": 587736,
    "governmentgrantsforresearchanddevelopmentexpenditures": 165699,
    "revenuefromgovernmentgrants": 134611,
    "nonoperatingincomeother": 587736,
    "netforeignexchangegainloss": -210647,
    "gainslossesondisposalsofpropertyplantandequipment": 968,
    "netgainlossesonchangesinfairvalueoffinanacialassetsandliabilitiesroutedthroughprofitorloss": 78038,
    "miscellaneousothergainslosses": 2342,
    "interestexpense": 431143,
    "interestonotherlongtermborrowing": 342540,
    "interestonloansfromshareholders": 327324,
    "interestexpensefromrelatedparties": 9627,
    "interestexpenseonleaseliabilities": 40425,
    "depreciationandamortisationexpense": 297758,
    "shorttermemployeebenefitsexpense": 4539663,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 132200,
    "expenseincomefromcashsettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 213636,
    "employeebenefitsexpense": 5085544,
    "employeebenefitsexpenserelatedtogeneralandadministrativefunction": 3856753,
    "employeebenefitsexpenserelatedtoresearchanddevelopment": 1228791,
    "accountingprofit": -16971289,
    "taxexpenseincomeatapplicabletaxrate": -2885119,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 84196,
    "taxcreditsrelatedtoexpenditureonresearchanddevelopment": 521234,
    "taxeffectoftaxlosses": 3022607,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 299550,
    "unusedtaxlossesforwhichnodeferredtaxassetrecognised": 151000000,
    "applicabletaxrate": 0.25,
    "decreaseinunappropriatedearningsduetoeffectofcorporatesurtaxrate": 0.05,
    "federalincometaxrate": 0.21,
    "stateincometaxrate": 0.087,
    "weightedaverageshares": 192226528,
    "sharebasedcompensationarrangementbysharebasedpaymentawardgrantedexpirationperiod": "P10Y",
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "The 241,142 bonus entitlement units granted under the 2018 LTIP will be one-third vested each year after the first, second, and third anniversary of the award. The 491,020 bonus entitlement units granted under the 2019 LTIP will be one-third vested each year after the first, second, and third anniversary of the award.",
    "percentageofdateofoptionsgranted": 0.25,
    "percentageofremainingdateofoptionsgranted": 0.75,
    "dateofgrantofsharebasedpaymentarrangement": "three years",
    "expensefromsharebasedpaymenttransactionswithemployees": 132200,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 104070,
    "reportingdatefairvalueofaward": 1.9,
    "recognizednetcompensationexpenses": 213636,
    "recognizedcompensationliabilitiescurrent": 1073593,
    "recognizedcompensationliabilitiesnoncurrent": 111990,
    "numberofoutstandingshareoptions": 3824062,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 501167,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 2.06,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 1.28,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 3824062,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 2.06,
    "weightedaveragefairvalueexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement": 1.62,
    "exercisepriceofoutstandingshareoptions2019": 2.06,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P3Y6M",
    "weightedaveragesharepriceshareoptionsgranted2019": 2.22,
    "exercisepriceshareoptionsgranted2019": 2.06,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.6625,
    "descriptionofoptionlifeshareoptionsgranted": 10,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0092,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 386950,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 128983,
    "liabilitiesarisingfromfinancingactivities": 15183421,
    "interestpaidclassifiedasfinancingactivities": 37935,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": -617912,
    "increasedecreasethroughotherchangesliabilitiesarisingfromfinancingactivities": -54163,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfrominterestexpense": 105899,
    "historicalvolatilityforsharessignificantunobservablesinputassets": 0.8463,
    "discountratesignificantunobservableinputsassets": 0.1,
    "increasedecreaseinfairvalueofdiscountrateunobservableinputs": 0.01,
    "decreaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsassets": 49,
    "percentageofwarrantsandconvertibilityrightdetermine": 0.15,
    "percentageofhistoricalvolatilityused": 0.926,
    "percentageofincreaseordecreaseonexchangerateofforeigncurrency": 0.05,
    "sensitivityanalysisrate": 0.05,
    "percentageofincreaseonexchangerateofforeigncurrency": 0.05,
    "percentageofdecreaseonexchangerateofforeigncurrency": 0.05,
    "borrowingsadjustmenttointerestratebasis": 0.01,
    "decreaseincreaseinpretaxlossduetohundredbasispointincreaseininterestrates": 194378,
    "financialassetsatamortisedcost": 14427678,
    "financialliabilitiesatamortisedcost": 24228678,
    "financialassetsexposedtoforeigncurrencyrisk": 458878,
    "financialassetsexchangerate": 0.7566,
    "financialassetscarryingvalue": 347190,
    "financialliabilitiesexposedtoforeigncurrencyrisk": 15722226,
    "financialliabilitiesexchangerate": 0.7566,
    "financialliabilitiescarryingvalue": 11895538,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -557417,
    "nameofultimateparentofgroup": "Key Management Personnel",
    "descriptionofnatureofrelatedpartyrelationship": "Key Management Personnel/Other",
    "cashadvancesandloansfromrelatedparties": 550000,
    "interestpayablefromrelatedparties": 67912,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2368143,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 99217,
    "keymanagementpersonnelcompensationcashsettledsharebasedcompensation": 138794,
    "keymanagementpersonnelcompensation": 2606154,
    "numberofreportablesegment": 1,
    "paymentsnotyetoccurredfromjointventureagreement": 2500000
  },
  {
    "date": "2019-12-31",
    "symbol": "ASLN",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "ASLAN Pharmaceuticals Ltd",
    "entitycentralindexkey": 1722926,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityinteractivedatacurrent": "Yes",
    "currentfiscalyearenddate": "--12-31",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": 189954970,
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "security12btitle": "Ordinary shares, par value NT$10 per share",
    "tradingsymbol": "ASLN",
    "securityexchangename": "NASDAQ",
    "notradingsymbolflag": "true",
    "entityfilenumber": "001-38475",
    "entityincorporationstatecountrycode": "E9",
    "contactpersonnelname": "Carl Firth",
    "entityaddressaddressline1": "83 Clemenceau Avenue #12-03 UE Square",
    "entityaddresscountry": "SG",
    "entityaddresspostalzipcode": 239920,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentregistrationstatement": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "cashandcashequivalents": 22203031,
    "prepayments": 68923,
    "currentassets": 2463003,
    "financialassetsatfairvaluethroughprofitorloss": 68256,
    "noncurrentfinancialassetsatfairvaluethroughothercomprehensiveincome": 132160,
    "propertyplantandequipment": 476646,
    "rightofuseassets": 727866,
    "intangibleassetsotherthangoodwill": 23113625,
    "longtermdeposits": 108076,
    "noncurrentassets": 1077536,
    "assets": 23349490,
    "tradeandothercurrentpayablestotradesuppliers": 1871843,
    "othercurrentpayables": 3246842,
    "currentleaseliabilities": 264543,
    "currentliabilities": 76155,
    "noncurrentfinancialliabilitiesatfairvaluethroughprofitorloss": 262350,
    "longtermborrowings": 10485464,
    "longtermborrowingsfromrelatedparties": 13750,
    "noncurrentleaseliabilities": 490835,
    "othernoncurrentliabilities": 184870,
    "noncurrentliabilities": 18569536,
    "liabilities": 23952764,
    "issuedcapital": 61366844,
    "capitalsurplus": 116495710,
    "retainedearnings": -179484825,
    "otherequityinterest": -55084,
    "equityattributabletoownersofparent": 1312767,
    "noncontrollinginterests": 1074081,
    "equity": 2386848,
    "equityandliabilities": 23349490,
    "revenuefromcontractswithcustomers": 3000000,
    "costofsales": 407259,
    "grossprofit": 2592741,
    "generalandadministrativeexpense": 8511699,
    "researchanddevelopmentexpense": 16586617,
    "operatingexpense": 25098316,
    "otheroperatingincomeexpense": -23073400,
    "profitlossfromoperatingactivities": -113923,
    "revenuefrominterest": 150610,
    "othergainslosses": -327558,
    "financecosts": 901612,
    "netnonoperatingincomeexpense": -1078560,
    "profitlossbeforetax": -46657535,
    "incometaxexpensecontinuingoperations": 408002,
    "profitloss": -49570,
    "othercomprehensiveincomebeforetaxgainslossesfrominvestmentsinequityinstruments": -55084,
    "comprehensiveincome": -113923,
    "profitlossattributabletoownersofparent": -64353,
    "profitlossattributabletononcontrollinginterests": -49570,
    "comprehensiveincomeattributabletoownersofparent": -64353,
    "comprehensiveincomeattributabletononcontrollinginterests": -49570,
    "basicanddilutedearningslosspershare": -0.29,
    "numberofsharesissued": 108800191,
    "issueofequity": 14733015,
    "increasedecreaseinnumberofordinarysharesissued": 5072022,
    "shareissuerelatedcost": 1444791,
    "increasedecreasethroughexerciseofoptions": 24000,
    "increasedecreasethroughexerciseofstockoptions": 29598,
    "increasedecreasethroughsharebasedpaymenttransactions": 42511,
    "increasedecreasethroughchangesinownershipinterestsinsubsidiariesthatdonotresultinlossofcontrol": 1376349,
    "equitycomponentoflongtermdebtborrowed": 44579,
    "othercomprehensiveincome": -55084,
    "netincreasedecreaseinnoncontrollinginterests": 2500000,
    "adjustmentsfordepreciationexpense": 441004,
    "adjustmentsforamortisationexpense": 4347,
    "adjustmentsforfairvaluegainslosses": 46985,
    "adjustmentsforfinancecosts": 901612,
    "adjustmentsforinterestincome": 150610,
    "adjustmentsforsharebasedpayments": 43783,
    "adjustmentsforgainlossondisposalspropertyplantandequipment": -74195,
    "adjustmentsforunrealisedforeignexchangelossesgains": 135344,
    "impairmentlossrecognisedinprofitorlossintangibleassetsandgoodwill": 23073400,
    "adjustmentforlossonleasemodification": 64287,
    "adjustmentsforincreasedecreaseinprepayments": 114676,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -3443894,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": -156874,
    "cashflowsfromusedinoperations": -25509280,
    "interestreceivedclassifiedasoperatingactivities": 150610,
    "interestpaidclassifiedasoperatingactivities": 36037,
    "incometaxespaidrefundclassifiedasoperatingactivities": 408002,
    "cashflowsfromusedinoperatingactivities": -1355768,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 2992,
    "proceedsfromsalesofpropertyplantandequipmentclassifiedasinvestingactivities": 5826,
    "increasedecreaseinrefundabledeposits": 2546,
    "cashflowsfromusedininvestingactivities": 5380,
    "proceedsfromborrowingsclassifiedasfinancingactivities": 3250000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 243265,
    "proceedsfromissuingshares": 14733015,
    "proceedsfromexerciseofoptions": 24000,
    "paymentsforshareissuecosts": 1172291,
    "proceedsfromcontributionsofnoncontrollinginterests": 2500000,
    "cashflowsfromusedinfinancingactivities": 2500771,
    "increasedecreaseincashandcashequivalents": 1145003,
    "leaseliabilities": 755378,
    "titleofnewifrs": "Amendments to IAS 1 and IAS 8 “Definition of Material”",
    "dateasatwhichentityplanstoapplynewifrsinitially": "2020-01-01",
    "effectivedateofnewstandards": "To be determined by IASB",
    "cashonhand": 1723,
    "balanceswithbanks": 22201308,
    "cash": 22203031,
    "financialliabilitiesatfairvaluethroughprofitorloss": 262350,
    "nameofinvestor": "ASLAN Pharmaceuticals Pte. Ltd.",
    "nameofsubsidiary": "Jaguahr Therapeutics Pte. Ltd.",
    "natureofactivities": "New drug research and development",
    "proportionofownershipinterestinsubsidiary": 0.55,
    "principalplaceofbusinessofsubsidiary": "Singapore",
    "proportionofvotingrightsheldbynoncontrollinginterests": 0.45,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 2992,
    "depreciationpropertyplantandequipment": 173056,
    "disposalspropertyplantandequipment": 209213,
    "usefullivesordepreciationratespropertyplantandequipment": "P3Y",
    "additionstorightofuseassets": 882670,
    "depreciationrightofuseassets": 267948,
    "discountratesoncapitalizedleasesinnominalterms": 0.06,
    "operatingleasesleaseterm": "P3Y",
    "increasedecreaseinleaseliabilities": 715365,
    "expenserelatingtoshorttermleasesforwhichrecognitionexemptionhasbeenused": 251549,
    "expenserelatingtoleasesoflowvalueassetsforwhichrecognitionexemptionhasbeenused": 7385,
    "cashoutflowforleases": 538236,
    "leasecommitments": 67935,
    "amortisationintangibleassetsotherthangoodwill": 4347,
    "impairmentlossrecognisedinprofitorlossintangibleassetsotherthangoodwill": 23073400,
    "usefullifemeasuredasperiodoftimeintangibleassetsotherthangoodwill": "P3Y",
    "shorttermemployeebenefitsaccruals": 1037213,
    "payablesforprofessionalfeescurrent": 923726,
    "currentrecognisedliabilitiesdefinedbenefitplan": 755787,
    "interestpayable": 392970,
    "otherliabilities": 137146,
    "borrowingsinterestrate": 0.05,
    "borrowingsinterestratebasis": "6% plus LIBOR",
    "longtermborrowingsincludinginterest": 3085660,
    "borrowingsredemptionandconversionpolicies": "(a) such outstanding principal amount and accrued and unpaid interest under the loan by (b) 90% of the volume-weighted average price of the Company’s ADSs on the date of the conversion notice. Each ADS represents five ordinary shares of the Company",
    "employercontributionpercentage": 0.06,
    "postemploymentbenefitexpensedefinedbenefitplans": 325059,
    "numberofsharesauthorised": 500000000,
    "authorizedcapital": 5000000000,
    "numberofsharesissuedandfullypaid": 189954970,
    "parvaluepershare": 10,
    "arisingfromissuanceofnewsharecapital": 108800191,
    "arisingfromemployeeshareoptions": 6274591,
    "changesinpercentageofownershipinterestsinsubsidiaries": 1376349,
    "equitycomponentoflongtermdebt": 44579,
    "othercomprehensiveincomenetoftaxgainslossesfrominvestmentsinequityinstruments": -55084,
    "regulatorymilestoneslinkedpaymentsestimated": 95000000,
    "noticeperiodforterminationofagreement": "P180D",
    "dateofagreement": "2016-10-31",
    "dateofagreementamended": "2018-03-31",
    "firstpaymentuponcommencement": 30000000,
    "salesmilestoneslinkedpaymentsestimated": 655000000,
    "percentageoflicensingrevenue": 0.1,
    "numberoftargetstoselect": 3,
    "numberofsharesreceivedinexchangeforsurrenderofresidualrights": 599445,
    "valueofsharesreceivedinexchangeforsurrenderofresidualrights": 255000,
    "numberofwarrantsreceivedinexchangeforsurrenderofresidualrights": 599445,
    "subscriptionprice": 0.32,
    "gainlossarisingfromderecognitionrecordedasotherincome": 187244,
    "netforeignexchangegainloss": -135413,
    "gainslossesondisposalsofpropertyplantandequipment": -74195,
    "gainlossonleasemodification": -64287,
    "gainslossesonfinancialassetsatfairvaluethroughprofitorloss": -46985,
    "miscellaneousothergainslosses": -6678,
    "interestexpense": 435684,
    "otherfinancecost": 374376,
    "interestonloansfromshareholders": 55515,
    "interestexpenseonleaseliabilities": 36037,
    "depreciationandamortisationexpense": 445351,
    "shorttermemployeebenefitsexpense": 5628025,
    "expensefromequitysettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 42511,
    "expenseincomefromcashsettledsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassets": 1272,
    "employeebenefitsexpense": 5996867,
    "employeebenefitsexpenserelatedtogeneralandadministrativefunction": 4210477,
    "employeebenefitsexpenserelatedtoresearchanddevelopment": 1786390,
    "accruedemployeescompensationandremunerationpercentage": 0.01,
    "currenttaxexpenseincome": 462713,
    "adjustmentsforcurrenttaxofpriorperiod": -54711,
    "accountingprofit": -46657534,
    "taxexpenseincomeatapplicabletaxrate": -7931781,
    "taxeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": 4115850,
    "taxcreditsrelatedtoexpenditureonresearchanddevelopment": 2474280,
    "taxeffectoftaxlosses": 5980036,
    "othertaxeffectsforreconciliationbetweenaccountingprofitandtaxexpenseincome": 322888,
    "taxeffectonwithholdingtax": 450000,
    "applicabletaxrate": 0.25,
    "decreaseinunappropriatedearningsduetoeffectofcorporatesurtaxrate": 0.05,
    "federalincometaxrate": 0.21,
    "stateincometaxrate": 0.087,
    "weightedaverageshares": 162392602,
    "dilutiveeffectofshareoptionsonnumberofordinaryshares": 13841879,
    "numberofinstrumentsotherequityinstrumentsgranted": 491020,
    "sharebasedcompensationarrangementbysharebasedpaymentawardgrantedexpirationperiod": "P10Y",
    "descriptionofvestingrequirementsforsharebasedpaymentarrangement": "No performance conditions were attached to the plan. The Company has no legal constructive obligation to repurchase or settle the options in cash.",
    "decreaseinexercisepriceforawardpreviouslygrantedpercentage": 0.5,
    "expensefromsharebasedpaymenttransactionswithemployees": 42511,
    "numberofinstrumentsgrantedinsharebasedpaymentarrangement": 491020,
    "retrospectiveshareconversionratio": 5,
    "grantdatefairvalueofaward": 2.92,
    "reportingdatefairvalueofaward": 2.03,
    "recognizednetcompensationexpenses": 1272,
    "recognizedcompensationliabilitiescurrent": 755787,
    "recognizedcompensationliabilitiesnoncurrent": 184870,
    "numberofoutstandingshareoptions": 501167,
    "numberofshareoptionsforfeitedinsharebasedpaymentarrangement": 197000,
    "numberofshareoptionsexercisedinsharebasedpaymentarrangement": 120000,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 501167,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 1.28,
    "weightedaverageexercisepriceofshareoptionsforfeitedinsharebasedpaymentarrangement2019": 1.28,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 0.2,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 1.28,
    "exercisepriceofoutstandingshareoptions2019": 1.28,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P7Y8M12D",
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 491020,
    "numberofotherequityinstrumentsforfeitedinsharebasedpaymentarrangement": 73053,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 56030,
    "considerationpaidreceived": 2500000,
    "proportionateshareofcarryingamountofnetassetsofsubsidiarytransferrednoncontrollinginterests": -1123651,
    "liabilitiesarisingfromfinancingactivities": 755378,
    "increasedecreasethroughfinancingcashflowsliabilitiesarisingfromfinancingactivities": -243265,
    "increasethroughnewleasesliabilitiesarisingfromfinancingactivities": 882670,
    "increasedecreasethroughotherchangesliabilitiesarisingfromfinancingactivities": -207877,
    "fairvalueofinvestmentsinequityinstrumentsdesignatedasmeasuredatfairvaluethroughothercomprehensiveincome": 132160,
    "transfersoutoflevel2intolevel3minimumperiodofinvestment": "P12M",
    "transfersoutoflevel2intolevel3offairvaluehierarchyassets": 187244,
    "significantunobservableinputassets": 41.87,
    "discountratesignificantunobservableinputsassets": 0.1,
    "increasedecreaseinfairvalueofdiscountrateunobservableinputs": 0.01,
    "decreaseinfairvaluemeasurementduetochangeinmultipleunobservableinputstoreflectreasonablypossiblealternativeassumptionsassets": 1652,
    "percentageofwarrantsandconvertibilityrightdetermine": 0.1412,
    "percentageofhistoricalvolatilityused": 0.926,
    "percentageofincreaseordecreaseonexchangerateofforeigncurrency": 0.05,
    "sensitivityanalysisrate": 0.05,
    "percentageofincreaseonexchangerateofforeigncurrency": 0.05,
    "percentageofdecreaseonexchangerateofforeigncurrency": 0.05,
    "borrowingsadjustmenttointerestratebasis": 0.01,
    "decreaseincreaseinpretaxlossduetohundredbasispointincreaseininterestrates": 151896,
    "financialassetsatfairvaluethroughprofitorlossmandatorilymeasuredatfairvalue": 68256,
    "financialassetsatamortisedcost": 22311107,
    "financialliabilitiesatfairvaluethroughprofitorlossdesignatedasuponinitialrecognition": 262350,
    "financialliabilitiesatamortisedcost": 21963089,
    "financialassetsexposedtoforeigncurrencyrisk": 2538168,
    "financialassetsexchangerate": 0.7431,
    "financialassetscarryingvalue": 1886160,
    "financialliabilitiesexposedtoforeigncurrencyrisk": 15126578,
    "financialliabilitiesexchangerate": 0.7431,
    "financialliabilitiescarryingvalue": 11240843,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -467734,
    "nameofultimateparentofgroup": "Others",
    "descriptionofnatureofrelatedpartyrelationship": "Key Management Personnel",
    "cashadvancesandloansfromrelatedparties": 552426,
    "interestpayablefromrelatedparties": 13750,
    "interestexpensefromrelatedparties": 13571,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2918180,
    "keymanagementpersonnelcompensationpostemploymentbenefits": 105449,
    "keymanagementpersonnelcompensationsharebasedpayment": 29176,
    "keymanagementpersonnelcompensation": 3052805,
    "numberofreportablesegment": 1
  }
]